Press Release Details

Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring


Oslo, Norway, 19 March 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management team is invited to present at upcoming conferences.
13th Annual BIO-Europe Spring, Vienna, Austria
Date: 25 March 2019
Presenter: Øystein Soug (CEO)
Panel discussion:
-    Art of multitrack deal: Keys to maximizing the value of your company
-    Time: 14:45 CET
DNB's 15th Annual Small & Medium Enterprises (SME) Conference, Oslo, Norway
Date: 4 April 2019
Presenter: Øystein Soug (CEO)
-    Time: 13:45 CET
3rd Annual European Neoantigen Summit, Amsterdam, The Netherlands
Date: 25 April 2019
Presenter: Erik Digman Wiklund (CBO)
-    Title: TG Mutant RAS Neoantigen Vaccine: Signal of Clinical Benefit in Resected Pancreatic Cancer
-    Time: 12:00 CET
Presentations will be available to download at ( after the event.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum - Corporate Communications
Phone: +47 9300 1773

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102's targeted path-to-market indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma, is expected to produce important proof-of-concept immune activation data in heavily pre-treated patients.

Targovax is also developing a neo-antigen cancer vaccine targeting tumors with oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program has shown strong RAS-specific immune activation and a signal of clinical efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently tested in a phase I trial in colorectal cancer, both as monotherapy and in combination with Keytruda (an anti-PD1 check point inhibitor).,c2766395